.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Fish and Richardson
Queensland Health
Accenture
McKinsey
Deloitte
Colorcon
Farmers Insurance
UBS
Julphar

Generated: November 21, 2017

DrugPatentWatch Database Preview

Millennium Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for MILLENNIUM PHARMS, and what generic alternatives to MILLENNIUM PHARMS drugs are available?

MILLENNIUM PHARMS has two approved drugs.

There are twelve US patents protecting MILLENNIUM PHARMS drugs.

There are two hundred and forty-three patent family members on MILLENNIUM PHARMS drugs in forty-seven countries and eleven supplementary protection certificates in nine countries.

Summary for Millennium Pharms

International Patents:243
US Patents:12
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Millennium Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for MILLENNIUM PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
bortezomib
For Injection3.5 mg/vial
VELCADE
11/20/2008

Non-Orange Book Patents for Millennium Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,772,536Proteasome inhibitors► Subscribe
7,109,323Formulation of boronic acid compounds► Subscribe
6,699,835 Formulation of boronic acid compounds► Subscribe
6,066,730 Boronic ester and acid compounds, synthesis and uses► Subscribe
9,175,018Boronate ester compounds and pharmaceutical compositions thereof► Subscribe
7,576,206Proteasome inhibitors and methods of using the same► Subscribe
6,465,433 Boronic ester and acid compounds, synthesis and uses► Subscribe
6,548,668 Boronic ester and acid compounds, synthesis and uses► Subscribe
7,915,236Proteasome inhibitors and methods of using the same► Subscribe
7,119,080Boronic ester and acid compounds, synthesis and uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Millennium Pharms Drugs

Country Document Number Estimated Expiration
South Korea20110043599► Subscribe
Germany69530936► Subscribe
Hong Kong1198254► Subscribe
Brazil122014008750► Subscribe
South Korea20170004031► Subscribe
European Patent Office2251344► Subscribe
Philippines12015501192► Subscribe
Portugal1660507► Subscribe
Norway2017016► Subscribe
Singapore10201701524X► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Millennium Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017010Lithuania► SubscribePRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR ESTERIAI, PAVYZDZIUI KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121
083Luxembourg► Subscribe91083, EXPIRES: 20190426
C0014France► SubscribePRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426
C008/2004Ireland► SubscribeSPC008/2004: 20050504, EXPIRES: 20190425
2017000025Germany► SubscribePRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2004 00012Denmark► Subscribe
C/GB04/021United Kingdom► SubscribePRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428
2017 00014Denmark► SubscribePRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123
0788360/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0151Netherlands► Subscribe300151, 20151027, EXPIRES: 20190425
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Medtronic
Argus Health
UBS
Citi
Chubb
Harvard Business School
Cantor Fitzgerald
Fish and Richardson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot